| Literature DB >> 33739429 |
Pei-Lun Kuo1,2, Alison R Huang2,3, Joshua R Ehrlich4,5, Judith Kasper6, Frank R Lin1,2,3,7, Michael M McKee5,8, Nicholas S Reed1,2,7,9, Bonnielin K Swenor1,2,9,10, Jennifer A Deal1,2,7,9.
Abstract
Importance: Impairments in vision or hearing are common and have been independently linked to higher risk of dementia in older adults. There is a limited understanding of the prevalence of concurrent functional vision and hearing impairment (dual sensory impairment) and its contribution to dementia risk. Objective: To examine the age-specific prevalence of functional dual sensory impairment among older adults, and to investigate the cross-sectional and 7-year longitudinal associations between functional dual sensory impairment and dementia. Design, Setting, and Participants: This cohort study of 7562 older adults used data from the US National Health and Aging Trends Study (NHATS), a nationally representative cohort study of community-dwelling, Medicare beneficiaries aged 65 years and older in the US. Participants in the study with complete data on hearing, vision, and dementia were included in analysis. Data were collected between 2011 and 2018, and between March 2018 and May 2020. Exposures: Self-reported functional sensory impairments (ie, no sensory impairment, functional vision impairment only, functional hearing impairment only, and functional dual sensory impairment). Main Outcomes and Measures: Age-specific prevalence of functional sensory impairments was calculated. Generalized linear regression with a complementary log-log link and a discrete time proportional hazards model with a complementary log-log link were used to assess the cross-sectional and 7-year longitudinal hazard of dementia.Entities:
Mesh:
Year: 2021 PMID: 33739429 PMCID: PMC8601132 DOI: 10.1001/jamanetworkopen.2021.1558
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Age-Specific Prevalence of Self-Reported Sensory Impairments
| Age group, y | No impairment, % (95% CI) | Impairment only, % (95% CI) | Dual sensory impairment, % (95% CI) | |
|---|---|---|---|---|
| Vision (n = 491) | Hearing (n = 1519) | |||
| 65-69 | 83.53 (81.48-85.57) | 5.07 (3.95-6.19) | 10.05 (8.24-11.86) | 1.35 (0.71-1.99) |
| 70-74 | 79.72 (77.42-82.02) | 3.68 (2.43-4.92) | 15.21 (12.98-17.44) | 1.39 (0.73-2.04) |
| 75-79 | 72.30 (69.70-74.91) | 4.46 (3.29-5.63) | 20.22 (17.78-22.66) | 3.02 (2.17-3.86) |
| 80-84 | 63.88 (60.67-67.08) | 6.85 (5.46-8.24) | 26.42 (23.56-29.27) | 2.86 (1.96-3.76) |
| 85-89 | 50.32 (46.84-53.80) | 8.52 (6.69-10.35) | 32.95 (29.69-36.21) | 8.21 (6.85-9.57) |
| ≥90 | 37.06 (33.23-40.90) | 10.62 (8.03-13.22) | 37.44 (33.52-41.37) | 14.87 (11.90-17.84) |
Sensory impairment categories are mutually exclusive.
Percentages weighted by age group.
Figure. Prevalence of Older Adults by Functional Vision and Hearing Impairment Status: National Health and Aging Trends Study, 2011
Sensory impairment categories are mutually exclusive. Error bars indicate 95% CIs.
Distribution of Baseline Characteristics Among Participants Stratified by Sensory Status
| Characteristics | No impairment, % (95% CI) | Impairment only, % (95% CI) | Dual sensory impairment, % (95% CI) | |
|---|---|---|---|---|
| Vision | Hearing | |||
| Age group, y | ||||
| 65-69 | 32.23 (31.08-33.39) | 26.26 (21.96-30.57) | 14.90 (12.52-17.29) | 12.30 (7.15-17.44) |
| 70-74 | 27.48 (26.45-28.52) | 17.01 (12.45-21.58) | 20.16 (17.65-22.66) | 11.27 (6.13-16.40) |
| 75-79 | 18.98 (17.91-20.04) | 15.71 (12.06-19.36) | 20.39 (17.84-22.95) | 18.65 (13.88-23.42) |
| 80-84 | 12.91 (12.07-13.75) | 18.57 (15.04-22.10) | 20.51 (18.46-22.57) | 13.61 (9.38-17.85) |
| 85-89 | 6.28 (5.62-6.94) | 14.27 (10.85-17.70) | 15.79 (13.96-17.63) | 24.12 (20.56-27.68) |
| ≥90 | 2.12 (1.79-2.46) | 8.17 (6.24-10.10) | 8.24 (6.97-9.51) | 20.06 (16.02-24.1) |
| Sex | ||||
| Female | 58.3 (56.54-60.06) | 69.81 (64.75-74.86) | 45.87 (43.46-48.27) | 59.99 (53.96-66.03) |
| Male | 41.7 (39.94-43.46) | 30.19 (25.14-35.25) | 54.13 (51.73-56.54) | 40.01 (33.97-46.04) |
| Education | ||||
| <High school | 19.05 (17.27-20.83) | 33.30 (28.17-38.43) | 23.11 (20.35-25.87) | 46.15 (38.38-53.92) |
| High school | 27.12 (25.48-28.75) | 26.76 (23.06-30.46) | 28.00 (25.93-30.08) | 27.26 (20.96-33.57) |
| >High school | 52.66 (50.31-55.00) | 39.26 (33.74-44.78) | 47.38 (44.50-50.25) | 24.30 (18.56-30.04) |
| Race | ||||
| Non-Hispanic White | 80.08 (78.25-81.90) | 72.08 (67.32-76.84) | 86.28 (84.21-88.35) | 70.79 (63.60-77.98) |
| Hispanic | 6.44 (5.35-7.52) | 9.98 (6.13-13.83) | 5.31 (4.07-6.55) | 17.39 (10.45-24.32) |
| Non-Hispanic Black | 8.90 (7.90-9.90) | 13.75 (11.51-15.99) | 3.76 (3.10-4.42) | 5.95 (4.07-7.83) |
| Other | 4.58 (3.45-5.71) | 4.19 (1.79-6.60) | 4.65 (3.34-5.96) | 5.87 (2.86-8.88) |
| Hypertension | 62.98 (61.40-64.55) | 72.16 (66.91-77.41) | 63.69 (61.22-66.15) | 71.27 (64.32-78.22) |
| Diabetes | 22.43 (21.10-23.76) | 32.82 (28.29-37.36) | 25.14 (22.43-27.85) | 32.93 (27.24-38.62) |
| Stroke | 8.11 (7.35-8.87) | 22.27 (18.52-26.01) | 11.69 (9.86-13.51) | 19.91 (15.22-24.61) |
| Heart attack | 12.11 (11.02-13.20) | 18.25 (14.45-22.05) | 19.54 (14.42-24.67) | 19.54 (14.41-24.67) |
| Heart disease | 15.30 (14.04-16.55) | 26.12 (21.56-30.66) | 21.31 (19.04-23.57) | 25.49 (19.96-31.02) |
| Lung disease | 14.30 (13.37-15.23) | 22.44 (16.90-27.98) | 16.57 (14.52-18.61) | 18.74 (13.38-24.10) |
| Cancer | 24.70 (23.18-26.22) | 23.32 (18.48-26.17) | 30.87 (28.73-33.02) | 24.01 (18.30-29.72) |
| Ever smoked | 52.81 (51.01-54.60) | 51.43 (45.72-57.15) | 53.47 (50.22-56.72) | 43.78 (35.48-52.07) |
| Dementia | 16.57 (15.03-18.11) | 39.58 (33.78-45.37) | 25.76 (22.69-28.83) | 55.99 (48.65-63.32) |
Sensory impairment categories are mutually exclusive. Summation within each category may be slightly lower than 100% because a very small proportion of data are missing.
Other includes all respondents who did not report as non-Hispanic White, Hispanic, or non-Hispanic Black in the National Health and Aging Trends Study data set.
Complementary Log-Log Regression Modeling the Cross-Sectional Association Between Sensory Impairment and Dementia
| Status of sensory impairment | Hazard ratio (95% CI) | ||
|---|---|---|---|
| Model 1 | Model 2 | Model 3 | |
| None | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Vision only | 2.83 (2.33-3.46) | 2.01 (1.66-2.43) | 1.89 (1.57-2.28) |
| Hearing only | 1.65 (1.44-1.91) | 1.17 (1.02-1.34) | 1.14 (1.00-1.31) |
| Dual sensory impairment | 4.57 (3.70-5.63) | 2.10 (1.66-2.67) | 2.00 (1.57-2.53) |
Unadjusted model.
Adjusted for age, sex, levels of education, and race/ethnicity.
Adjusted for age, sex, levels of education, race/ethnicity, smoking history, hypertension, diabetes, stroke, heart attack, heart disease, lung disease, and cancer.
Discrete Time Survival Analysis Modeling the Association Between Sensory Impairment and Incident Dementia
| Status of sensory impairment | Hazard Ratio (95% CI) | ||
|---|---|---|---|
| Model 1 | Model 2 | Model 3 | |
| None | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Vision only | 1.85 (1.49-2.29) | 1.45 (1.16-1.80) | 1.40 (1.12-1.74) |
| Hearing only | 1.44 (1.27-1.63) | 1.11 (0.97-1.26) | 1.09 (0.95-1.24) |
| Dual sensory impairment | 3.05 (2.29-4.06) | 1.54 (1.14-2.07) | 1.50 (1.12-2.02) |
The proportional hazard assumption was checked, and time-varying hazard ratios were allowed when the assumption was violated. The proportional hazard assumption held for the functional hearing impairment group (vs no impairment) and for the functional vision impairment group (vs no impairment) across the 7-year follow-up period. For the functional dual sensory impairment group (vs no impairment), the proportional hazard assumption held across the first 4-year follow-up period, but did not hold after the 4-year follow-up. Time-varying hazard ratios were allowed between the dual sensory impairment group (vs no impairment) after 4-year follow-up.
Unadjusted model.
Adjusted for age, sex, levels of education, and race/ethnicity.
Adjusted for age, sex, levels of education, race/ethnicity, smoking history, hypertension, diabetes, stroke, heart attack, heart disease, lung disease, and cancer.